SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
04 Décembre 2023 - 10:13PM
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage
biopharmaceutical company focused on severe rare diseases and
cancer, announced today that it has commenced an underwritten
public offering of $250.0 million of shares of its common stock.
All of the shares in the offering will be sold by
SpringWorks. In addition, SpringWorks expects to grant the
underwriters a 30-day option to purchase up to an additional $37.5
million of shares of its common stock in the offering.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen
and Company, LLC and Guggenheim Securities, LLC are acting as joint
book-running managers for the offering. The proposed offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
An automatic shelf registration statement on Form S-3ASR
relating to these securities has been filed with the Securities and
Exchange Commission (SEC) and has become effective.
The offering will be made only by means of a prospectus and
prospectus supplement that form part of the automatic shelf
registration statement. A copy of the preliminary prospectus
supplement and accompanying prospectus relating to the offering
will be filed with the SEC and may be obtained, when available,
from: Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, or by telephone at
(866) 471-2526 or by email at prospectus-ny@ny.email.gs.com, J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1115 Long Island Avenue, Edgewood, NY 11717, or by by telephone at
(866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com, Cowen
and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by
email at Prospectus_ECM@cowen.com or by telephone at (833)
297-2926, or Guggenheim Securities, LLC, Attention: Equity
Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY
10017, or by telephone at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company
applying a precision medicine approach to developing and delivering
life-changing medicines for people with severe rare diseases and
cancer.
Founded in 2017, SpringWorks has a diversified targeted oncology
pipeline spanning solid tumors and hematological cancers, including
clinical trials in rare tumor types and highly prevalent,
genetically defined cancers. OGSIVEO™, approved in the United
States for the treatment of adult patients with progressing desmoid
tumors who require systemic treatment, is SpringWorks’ first U.S.
Food and Drug Administration (FDA) approved therapy. SpringWorks’
strategic approach and operational excellence in clinical
development have enabled it to rapidly advance its lead product
candidates into late-stage trials and enter into multiple
collaborations with innovators in industry and academia to unlock
the full potential for its portfolio and create more solutions for
patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding SpringWorks’ expectations with respect to the completion,
timing and size of the proposed public offering and granting the
underwriters a 30-day option to purchase additional shares. The
words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed offering, and other risks identified in the
section entitled “Risk Factors” in Item 1A of Part II of
SpringWorks’ Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023, as well as discussions of potential risks,
uncertainties and other important factors in SpringWorks’
subsequent filings with the SEC. SpringWorks cautions you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. SpringWorks disclaims any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent SpringWorks’ views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date.
SpringWorks Contacts:
Kim DiamondVice President, Communications and Investor
RelationsPhone: 203-561-1646 Email: kdiamond@springworkstx.com
Samantha Hilson SandlerSenior Director, Investor RelationsPhone:
203-461-5501Email: samantha.sandler@springworkstx.com
SpringWorks Therapeutics (NASDAQ:SWTX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
SpringWorks Therapeutics (NASDAQ:SWTX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024